Warning About Incivek Promotion Issued by FDA
June 1, 2012
Vertex warned over misleading hep C drug promotion
Boston Business Journal by Julie M. Donnelly, Reporter
Date: Wednesday, May 30, 2012
The U.S. Food and Drug Administration has issued a letter to Vertex Pharmaceuticals (Nasdaq: VRTX) saying the company published a misleading “branded story” promoting its drug for hepatitis C, Incivek. The FDA is demanding that the Cambridge, Mass.-based company, which won FDA approval for the drug in May of 2011, stop disseminating the materials in question.
The letter reads in part, “The branded story is misleading because it overstates the efficacy, omits material facts and minimizes important risk information about the drug product.”
Continue reading this entire article:
Hepatitis C Update: Is it Safe to Get a Tattoo?
Gap in Hepatitis B Diagnosis and Treatment